Xiaofeng Jin et al. have indicated that SPOP is a tumor suppressor in DLBCL and defective mutations in the SPOP–MyD88 binding interface may contribute to aberrant MyD88/NF-κB activation [27]. The gene discussed is MYD88; the disease is diffuse large B-cell lymphoma.